Gastric cancer is the second most commonly diagnosed fatal cancer in the world 1 and is characterized by a very poor prognosis in its more advanced stages 2 • Gastric adenocarcinoma is classified into two distinct histological typesintestinal and diffuse 3 . The intestinal type predominates in high-risk populations, is more common in the elderly and is preceded by a continuum of histological changes in the gastric mucosa including chronic active gastritis, atrophy, intestinal metaplasia and dysplasia". The diffuse type is less common, occurring more frequently in low-risk populations and mostly in younger people. No well-defined precancerous lesions have been described for this type of gastric cancer 4 , 5. Several factors such as age, family history and diet have been reported to be associated with gastric cancer. In 1994, the International Agency for Cancer Research recognized a cause-and-effect relationship between Helicobacter pylori and gastric adenocarcinoma and classified H. pylori as a group I (definite) carcinopen''. reveal striking similarities. In populations born after the Second World War, a decrease of 30-40% in the incidence of gastritis has been observed, which closely corresponds with a mean decrease of 30% in the incidence of gastric cancer in this population11.
Three nested case-controls studies have compared the prevalence of H. pylori-lgG antibodies in stored serum between individuals who subsequently developed gastric cancer and age matched controls I 2 -14 . All three demonstrated that the presence of H. pylori antibodies was significantly associated with an increased relative risk of developing gastric cancer (Table 1) . For patients diagnosed more than 14 years after blood donation, the odds ratio increased to 8.7 (95% CI 2.7-45) and the seroprevalence of H. pylori was 90%15 ( Table 2) . (Figure 1 ).
Regulation and control of birth, differentiation and loss of cells are key factors in the maintenance of normal growth of tissues-". Cell proliferation is controlled at two levels. The cell cycle is controlled by factors including p34 cdc2 and cyclins 30 and cell growth is controlled by growth factors 31 . Increased cell proliferation is a common feature in the pathogenesis of many human cancers and may play a role in carcinogenesis by converting DNA adducts to mutation. In a recent stud y 32, the epithelial cell proliferation of gastric antral mucosa was determined, by means of the bromodeoxyuridine immunohistochemical technique, in patients with normal antral mucosa, chemically induced gastritis or H. pylori-associated gastritis. The patients with H. pylori-associated gastritis had a higher cell turnover than controls (patients with normal mucosa or chemically induced gastritis) but cell proliferation became normal after eradication of H. pylori 33. In addition increased epithelial cell proliferation was detected in H. pylori-associated atrophic gastritis, intestinal metaplasia, dysplasia and gastric cancer-". These effects of H. pylori on the cell kinetics of the In case-control studies, the prevalence of H. pylori antibodies at the time of clinical diagnosis of gastric cancer has been compared with that in controls. Table 3 summarizes four studies of this type l 6--19 . Three showed a significant association between the prevalence of H. pylori and gastric cancer 16--18 . Several large population-based studies have compared the prevalence of H. pylori and the incidence of gastric cancer. The EUROGAST study, involving 17 separate populations from 11 European countries, Japan and the USA, produced an estimated relative risk of 6.0 8 . These studies provide evidence of a strong worldwide association between H. pylori and gastric cancer, clearly implicating the bacterium in the pathogenesis of this disease.
HUMAN MODEL FOR GASTRIC CARCINOGENESIS
Intestinal-type gastric carcinoma develops through a sequence of histological events from normal gastric mucosa through superficial gastritis, chronic gastritis, atrophy, intestinal metaplasia and dysplasia and eventually cancer", Numerous studies have demonstrated the relationship between gastric colonization by H. pylori and chronic active gastritis 2 0-22 • Initially, chronic active gastritis is of the superficial non-atrophic type 23 . With time, the superficial gastritis may become atrophic with deeper extension of the inflammatory cells and loss of antral and fundal glands 23 . A significant association between the precursor lesion intestinal metaplasia and H. pylori has been dcmonstrated/".
Intestinal metaplasia may be considered as a defensive strategy adopted by the mucosa to eradicate H. pylori, as the bacterium will only colonize gastric epithelium. Intestinal metaplasia can be subdivided on the basis of cell differentiation and mucin secretion into type I, type IIand type III25, the last being closely associated with gastric canccr/". We have found that H. pylori is significantly less prevalent in type II and type III intestinal metaplasia than in type 1 27 . Our hypothesis is that, with the progression of intestinal metaplasia from type I to type III, the mucosal architecture becomes less hospitable to H. pylori colonization. We have also shown that, in patients with persistent H. pylori infection, after a follow-up of greater than gastric epithelium provide further evidence of an association between the bacterium and gastric cancer. Several studies have identified abnormalities of tumour suppressor genes, oncogenes and growth factors in the pathogenesis of gastric carcinoma, but as yet these molecular alterations have not been directly attributed to H. pylori infection. It must be stated that these genetic abnormalities are found in the latter stages of gastric cancer development. They may, however, be the end-result of previous H. pylori infection.
GASTRIC JUICE MUTAGENICITY
Epidemiological evidence suggests a strong association between high ascorbic acid intake and low incidence of gastric cancer. The protective effect of ascorbic acid may be due to its ability to inactivate reactive oxygen species as well as its nitrite-scavenging effects. Patients with peptic ulcer disease, gastritis, pernicious anaemia and gastric cancer have lower concentrations of ascorbic acid in the gastric juice than do controls 35 , 36 . Ascorbic acid is secreted by the stomach across the gastric mucosa into the gastric juice against a concentration gradient 37 . Banerjee et al. 38 examined the effect of H. pylori on the secretion of ascorbic acid into the gastric juice by measuring fasting plasma and gastric juice ascorbic acid concentrations in patients with and without H. pylori infection and also before and after its eradication. Gastric juice ascorbic acid concentrations in the H. pylori-positive patients were significantly lower than in the H-negative controls despite similar plasma ascorbic acid concentrations in the two groups.
After eradication of H. pylori, gastric juice ascorbic acid increased to near normal levels.
Nitrites and N-nitroso compounds have been implicated in gastric carcinogcncsis". Atrophic gastritis, caused by chronic H. pylori infection, results in hypochlorhydria-a condition that leads to bacterial overgrowth. Nitratereducing bacteria may convert nitrate to nitrite, which may be metabolized to N-nitroso compounds.
Reactive oxygen species damage DNA, causing strand breaks, translocations and deletions'v. H. pylori-associated inflammation causes excessive production of reactive oxygen species which may result in DNA injury in stem cells. After successful eradication of H. pylori, the reactive oxygen species activity is substantially reduccd'".
In summary, H. pylori infection causes a reduction of ascorbic acid secretion, an accumulation of N-nitroso compounds and enhanced production of reactive oxygen species.
BACTERIAL PATHOGENICITY
The clinical outcome of H. pylori infection is very variable.
Most hosts remain symptom-free, some develop peptic ulcers and very few progress to gastric cancer. H. pylori strains may differ in their virulence. Antibodies against a H.
pylori protein can be detected in gastric biopsies of H. pyloriinfected individuals and are strongly associated with peptic ulcer disease and severe gastritis 42 . These antibodies are associated with the presence of the cytotoxin associated gene (caBA). Strains that express the caBA-antigen induce more rapid secretion of interleukin-8 (IL-8) in gastric epithelial cell lines than do caBA-negative strainst '. Gastric epithelial IL-8 expression is increased in chronic H. pylori-associated gastritis and in gastric carcinoma''".
Certain strains of H. pylori produce a vacuolating cytotoxin that induces cytopathic vacuolation in gastric epithelial cell lines. The gene encoding for this toxin is known as vacA45 and its mosaic structure has been determined. It consists of one of two signal sequence types, s 1 and s2, and one of two mid-region types, m 1 and m2. In areas of high gastric cancer incidence, the signal sequence type s1 is more common than in areas with low rates of gastric canccr'". Strains possessing the s1 signal sequence seem to be more virulent and may play an important role in the development of gastric cancer.
HELICOBACTER PYLORI AND GASTRIC LYMPHOMA
Primary non-Hodgkin's lymphomas of the stomach account for 1-7% of all gastric malignancies. Mucosa-associated lymphoid tissue is not found in the normal stomach. Chronic H. pylori infection, however, results in a lymphocytic infiltrate and the formation of lymphoid follicles 47 . Eradication of H. pylori leads to regression of these changes 48 . Epidemiological studies, based on stored serum samples, suggest that patients with low-grade B-cell mucosaassociated lymphoid tissue (MALT) lymphoma are more likely to be infected with H. pylori than matched controls'i". In vitro, cells from low-grade B-cell MALT lymphomas are H. pylori and T-cell depcndcnti''.
In an intervention study, Wotherspoon et al. 51 gave H. pylori eradication therapy to six ratients with histological and molecular genetic evidence of low-grade B-cell MALT lymphoma and concomitant H. pylori infection. H. pylori was successfully eradicated in all six. After repeated biopsies 4---10 months after eradication, five of the patients showed no evidence of lymphoma. In the largest and most recent study 52, 33 patients with low-grade B-cell MALT lymphoma, associated with H. pylori-gastritis, were treated with eradication therapy. All became H. pylori-negative. On histological assessment 23 patients showed complete regression and four partial regression of lymphoma. During a 1 year follow-up there were no relapses. Long-term followup studies, however, are needed to determine whether these remissions are lasting.
CANCER PREVENTION
Two strategies for the prevention of gastric cancer through control of H. pylori have been proposed. Vaccination is a long-term prospect and, as yet, no vaccine is available. It would need to be administered early in life and, as gastric cancer usually occurs late in life, at least 50 years would elapse before any benefits were apparent.
Effective and inexpensive regimens are now becoming available for eradication of H. pylori. Thus we can consider screening large populations and treating those infected as a means of cancer prevention. Screening programmes would employ non-invasive methods for H. pylori detection. Serological testing for IgG antibodies against H. pylori has its disadvantages since a positive result may indicate previous infection. The 13C urea breath test is highly sensitive and specific and does not expose the patient to radiation. This test has been modified to render it user-friendly and ideal for a screening programme-3 .
For any screening strategy to be cost-effective several factors must be taken into account. The prevalence of H. pylori infection is decreasing and this decline is accompanied by a parallel decrease in the incidence of gastric cancer. It would be necessary to establish a screening programme in an age group sufficiently old that reinfection would not occur and sufficiently young that eradication would still have a beneficial effect on cancer prevention.
Clearly more research is needed in drug development and in determination of the natural history of H. pyloriassociated gastric cancer in order to optimize any screening strategy. However, with the knowledge that H. pylori results in a ninefold increased risk for the development of the world's second most commonly diagnosed fatal cancer, screening in symptom-free individuals cannot be far over the medical horizon.
